share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q:2024財年二季報
美股SEC公告 ·  2024/08/12 17:31

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc. reported a net loss of $5.4 million for Q2 2024, compared to $2.1 million in Q2 2023, with total operating expenses increasing to $3.1 million from $1.3 million year-over-year. The company ended the quarter with $0.2 million in cash and cash equivalents, down from $4.2 million at the end of 2023, reflecting ongoing investments in research and development activities.The company recently strengthened its pipeline through a significant licensing agreement with AstraZeneca on August 7, 2024, gaining exclusive rights to HK-4 Glucokinase activators and a myeloperoxidase inhibitor. To support operations, Conduit secured a $2.65 million senior secured promissory note from Nirland Limited and issued 12.5 million shares of common stock.Management has identified the need for additional financing to fund operations for the next 12 months, with working capital requirements estimated at $17.1 million. The company received a Nasdaq deficiency notice on August 12, 2024, regarding its stock price falling below $1.00 per share minimum requirement, with until February 10, 2025, to regain compliance.
Conduit Pharmaceuticals Inc. reported a net loss of $5.4 million for Q2 2024, compared to $2.1 million in Q2 2023, with total operating expenses increasing to $3.1 million from $1.3 million year-over-year. The company ended the quarter with $0.2 million in cash and cash equivalents, down from $4.2 million at the end of 2023, reflecting ongoing investments in research and development activities.The company recently strengthened its pipeline through a significant licensing agreement with AstraZeneca on August 7, 2024, gaining exclusive rights to HK-4 Glucokinase activators and a myeloperoxidase inhibitor. To support operations, Conduit secured a $2.65 million senior secured promissory note from Nirland Limited and issued 12.5 million shares of common stock.Management has identified the need for additional financing to fund operations for the next 12 months, with working capital requirements estimated at $17.1 million. The company received a Nasdaq deficiency notice on August 12, 2024, regarding its stock price falling below $1.00 per share minimum requirement, with until February 10, 2025, to regain compliance.
Conduit Pharmaceutical Inc. 報告稱2024年第二季度淨虧損爲540萬美金,較2023年第二季度的210萬美金有所增加,營業費用同比增加至310萬美金,從130萬美金上升。公司在本季度末現金及現金等價物爲20萬美金,較2023年底的420萬美金下降,這反映了公司在研究和開發活動中的持續投資。公司最近通過與阿斯利康在2024年8月7日簽署的重要許可協議,增強了其產品管道,獲得了Hk-4 葡萄糖激酶激活劑和髓過氧化物酶抑制劑的獨佔權利。爲了支持運營,Conduit從Nirland Limited獲得了265萬美金的高級擔保本票,併發行了1250萬股普通股。管理層已識別出在未來12個月內爲運營提供額外融資的需求,流動資金需求估計爲1710萬美金。公司在2024年8月12日收到了納斯達克的缺陷通知,因其股票價格低於每股1.00美金的最低要求,並有直到2025年2月10日的時間來恢復合規。
Conduit Pharmaceutical Inc. 報告稱2024年第二季度淨虧損爲540萬美金,較2023年第二季度的210萬美金有所增加,營業費用同比增加至310萬美金,從130萬美金上升。公司在本季度末現金及現金等價物爲20萬美金,較2023年底的420萬美金下降,這反映了公司在研究和開發活動中的持續投資。公司最近通過與阿斯利康在2024年8月7日簽署的重要許可協議,增強了其產品管道,獲得了Hk-4 葡萄糖激酶激活劑和髓過氧化物酶抑制劑的獨佔權利。爲了支持運營,Conduit從Nirland Limited獲得了265萬美金的高級擔保本票,併發行了1250萬股普通股。管理層已識別出在未來12個月內爲運營提供額外融資的需求,流動資金需求估計爲1710萬美金。公司在2024年8月12日收到了納斯達克的缺陷通知,因其股票價格低於每股1.00美金的最低要求,並有直到2025年2月10日的時間來恢復合規。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息